A monocyte mitochondrial superoxide cutoff accurately stratified short-term survival risk in hepatocellular carcinoma.
Results from the TALENTACE trial suggest that atezolizumab plus bevacizumab and on-demand TACE may be a “new and effective treatment option,” according to Guohong Han, MD, PhD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback